Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes
NM Haynes, MJ Smyth, MH Kershaw… - Cancer Immunology …, 1999 - Springer
A chimeric receptor, consisting of the single-chain variable (scFv) domains of an anti-erbB-2
mAb linked via a CD8 membrane-proximal hinge to the Fc receptor γ chain, was expressed …
mAb linked via a CD8 membrane-proximal hinge to the Fc receptor γ chain, was expressed …
Bispecific monoclonal antibody therapy of B-cell malignancy
GJ Weiner, GC De Gast - Leukemia & lymphoma, 1995 - Taylor & Francis
Bispecific monoclonal antibodies (bsAbs) that recognize CD3 with one arm and a tumor
associated antigen with the other arm can retarget T-cells toward tumor cells in an MHC …
associated antigen with the other arm can retarget T-cells toward tumor cells in an MHC …
In Vitro Cytotoxic Targeting by Human Mononuclear Cells and Bispecific Antibody 2B1, Recognizing c-erbB-2 Protooncogene Product and Fcγ Receptor III
ST Hsieh-Ma, AM Eaton, T Shi, DB Ring - Cancer research, 1992 - AACR
Bispecific murine monoclonal antibody 2B1, possessing dual specificity for the human c-erb
B-2 protooncogene product and human Fcγ receptor III (CD16) was evaluated for the ability …
B-2 protooncogene product and human Fcγ receptor III (CD16) was evaluated for the ability …
Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus
W Stohl - Clinical immunology and immunopathology, 1992 - Elsevier
No differences in proliferation induced by the anti-CD3 MAb 454 were detected between
systemic lupus erythematosus (SLE) and normal peripheral blood mononuclear cells …
systemic lupus erythematosus (SLE) and normal peripheral blood mononuclear cells …
Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic
D Mezzanzanica, S Canevari, MI Colnaghi - International Journal of …, 1992 - Springer
We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which
exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa …
exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa …
Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells
M Massaia, C Attisano, S Peola, L Montacchini… - 1993 - ashpublications.org
We have recently shown that peripheral blood T cells of multiple myeloma (MM) patients are
very susceptible to stimulation of the T-cell receptor/CD3 complex with anti-CD3 monoclonal …
very susceptible to stimulation of the T-cell receptor/CD3 complex with anti-CD3 monoclonal …
Tumor‐growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T‐cell co‐stimulation via CD28
L Grosse‐Hovest, M Brandl, M Dohlsten… - … journal of cancer, 1999 - Wiley Online Library
The ability of bispecific antibodies with anti‐tumor× anti‐CD3 specificity to mediate the killing
of tumor cells by activated T cells has been demonstrated in many in vitro experiments …
of tumor cells by activated T cells has been demonstrated in many in vitro experiments …
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 …
H Bohlen, O Manzke, S Titzer, J Lorenzen, D Kube… - Cancer research, 1997 - AACR
Bispecific CD3× antitumor antibodies in combination with coactivating CD28 antibodies can
induce resting T cells to proliferate and to lyse syngeneic tumor cells (M. Azuma et al., J …
induce resting T cells to proliferate and to lyse syngeneic tumor cells (M. Azuma et al., J …
Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease
L da Costa, C Renner, F Hartmann… - Cancer chemotherapy …, 2000 - Springer
For the treatment of Hodgkin lymphoma, bispecific monoclonal antibodies (bi-mAbs) were
established which recognize the Hodgkin-associated CD30 antigen with one arm and the …
established which recognize the Hodgkin-associated CD30 antigen with one arm and the …
Activation of multiple effector mechanisms to enhance tumor lmmunotherapy
JA Hank, MR Albertini, J Schiller… - Journal of …, 1993 - journals.lww.com
Recent technical advances have enabled the generation of clinical reagents for
immunotherapy. Currently, treatment protocols combining both interleukin-2 (IL-2) and tumor …
immunotherapy. Currently, treatment protocols combining both interleukin-2 (IL-2) and tumor …